{"id":50990,"date":"2026-04-18T07:39:59","date_gmt":"2026-04-18T07:39:59","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/50990\/"},"modified":"2026-04-18T07:39:59","modified_gmt":"2026-04-18T07:39:59","slug":"roche-earnings-edge-up-5-as-forex-effects-weigh-on-drug-sales-growth-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/50990\/","title":{"rendered":"Roche earnings edge up 5% as forex effects weigh on drug sales growth"},"content":{"rendered":"

Forex effects damp Roche’s drug sales growthCEO Schinecker’s tenure has seen drug trial winsRoche invests in obesity drugs despite competitionFRANKFURT, Jan 29 (Reuters) – Roche’s (ROG.S), opens new tab<\/a> adjusted operating income rose by a lower-than-expected 5% in 2025 as gains in drugs such as Ocrevus against multiple sclerosis and Hemlibra against haemophilia were blunted by a weak U.S. dollar weighing on overseas sales.<\/p>\n

The lower-than-expected earnings cloud a positive turnaround in the track record of CEO Thomas Schinecker, close to three years in office, after he oversaw recent drug trial wins that have sharply boosted the stock.<\/p>\n

Sign up here.<\/a><\/p>\n

Operating profit, adjusted for special items, came in at<\/p>\n

21.8 billion Swiss francs ($28.48 billion) in 2025, the Swiss drugmaker said in a statement on Thursday, just shy of a market consensus of 22 billion francs cited by analysts.<\/p>\n

The group also said it expects 2026 group sales to grow in the mid-single-digit percentage range, while targeting core earnings per share growth in the high-single-digit range.<\/p>\n

Revenues in Ocrevus rose 9% to 7.0 billion francs, and in Hemlibra by 11% to 2.7 billion francs, both slightly more than expected, while gains in eye drug Vabsymo and breast cancer therapy Phesgo came in somewhat below market consensus.<\/p>\n

Roche shares fell 1.9% to a three-week low shortly after the 0800 GMT open.<\/p>\n

US DOLLAR WEAKNESS<\/p>\n

The U.S. dollar lost about 12% against the Swiss franc last year and it is down by more than 3% so far in 2026.<\/p>\n

Group revenues of 61.5 billion francs, up 2%, were broadly in line with the market view.<\/p>\n

The stock has gained about 25% since mid-November as two major study readouts provided a much-needed boost to the company’s development credentials.<\/p>\n

In November, an experimental multiple sclerosis<\/a> drug succeeded in a pivotal trial, followed within weeks by Sanofi (SASY.PA), opens new tab<\/a> running into delays in the regulatory review of its rival treatment<\/a>.Last month, a Roche drug candidate was shown to cut the recurrence risk<\/a> in a common form of breast cancer.Schinecker has invested heavily in obesity drugs, challenging dominant players Novo Nordisk (NOVOb.CO), opens new tab<\/a> and Eli Lilly (LLY.N), opens new tab<\/a>.Its leading candidate cut body weight by as much as 22.5% in a mid-stage trial, Roche said on Tuesday<\/a>, but market concerns about its rivals’ long head start have prevailed.<\/p>\n

($1 = 0.7655 Swiss francs)<\/p>\n

Reporting by Ludwig Burger, Editing by Friederike Heine, Shri Navaratnam, Alexandra Hudson<\/p>\n

Our Standards: The Thomson Reuters Trust Principles., opens new tab<\/a><\/p>\n

Purchase Licensing Rights<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Forex effects damp Roche’s drug sales growthCEO Schinecker’s tenure has seen drug trial winsRoche invests in obesity drugs…\n","protected":false},"author":2,"featured_media":50991,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[124],"tags":[15510,4967,15523,15524,15513,26140,26137,26141,29176,26138,26143,15528,18220,26144,10889,10895,10886,10891,2082,10873,15525,2228,29175,18215,15515,15517,15518,15519,15521,23811,29172,29171,134,29174,18230,18224,15526,10872,29173],"class_list":{"0":"post-50990","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-roche","8":"tag-bact","9":"tag-biz","10":"tag-ceeu","11":"tag-ch","12":"tag-cmpny","13":"tag-destabn","14":"tag-destabx","15":"tag-destbnx","16":"tag-destd","17":"tag-deste","18":"tag-destfun","19":"tag-destoukbsm","20":"tag-destoushem","21":"tag-destpco","22":"tag-destpsc","23":"tag-destrbn","24":"tag-destrnp","25":"tag-destucdptest","26":"tag-emea","27":"tag-europ","28":"tag-fin","29":"tag-gen","30":"tag-genhlt","31":"tag-hea","32":"tag-heca","33":"tag-phar","34":"tag-phar1","35":"tag-phmr","36":"tag-publ","37":"tag-res","38":"tag-resf","39":"tag-rhpicommercial-strategy","40":"tag-roche","41":"tag-rulesresults","42":"tag-topcmb","43":"tag-topicpharma-healthcare-business-health","44":"tag-topnws","45":"tag-weu","46":"tag-womhea"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116424581133342289","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/50990","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=50990"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/50990\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/50991"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=50990"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=50990"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=50990"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}